What Does a “Longevity Supplement” Actually Have to Prove?

There may be no word in consumer health having a bigger moment than “longevity.”

Longevity clinics. Longevity diets. Longevity molecules. Longevity powders. Longevity stacks. Longevity supplements.

Some of the products behind that word contain genuinely interesting compounds. Some ingredients have decades of laboratory research. Others affect molecular pathways that biologists believe are important to aging.

That science can be valuable.

But there is a gap hiding inside the language.

A compound being associated with aging biology is not the same thing as a finished product demonstrating an effect on aging. And twelve ingredients, each with an impressive list of citations, do not automatically become a proven longevity formula when they are combined in a packet.

Studies have found that combinations of longevity molecules can behave differently from their parts and even shorten lifespan, as we've covered here. An intervention can make perfect mechanistic sense and fail when tested in a living animal. Something that works in a mouse can fail in a person. Something that changes a molecular biomarker may never meaningfully change how an organ functions.

This is not a reason to dismiss longevity science. It is a reason to demand more of it.

The question, then, is not whether a supplement contains ingredients connected to longevity.

The harder question is: what happens when you actually test the intervention?

The word “longevity” has a standards problem

The evidence behind “longevity” products varies enormously

There is a common chain of reasoning in supplements.

Ingredient A affects pathway B. Pathway B has been implicated in aging. Therefore, a product containing Ingredient A is marketed for longevity.

Nothing about that argument is necessarily dishonest. But each step answers a different scientific question.

A cell-culture study tells us what may happen to cells under specific laboratory conditions. An ingredient trial tells us something about that ingredient. A biomarker study tells us something about that biomarker. An animal lifespan experiment asks whether an intervention changes survival in a living organism. And a randomized human trial asks whether the actual intervention changes a predefined outcome in people. And even within people, there are many fundamental questions, including whether it impacted a blood biomarker, or the actual organ's function.

These are not interchangeable forms of evidence. They are layers.

01Ingredient rationaleA reason to believe a compound matters to aging biology.
02Cellular mechanismA defined effect on an aging-related pathway in cells.
03Finished formula in vitroThe actual combination tested under laboratory conditions.
04Animal healthspan + lifespanSurvival and function measured in a living organism.
05Human biomarkers / pilotsEarly signals in people; exploratory, not definitive.
06Randomized human functionThe finished formula versus placebo, on a predefined outcome.

Each step answers a harder and more directly relevant question.

A product does not become scientifically stronger by blurring those layers together. It becomes stronger by climbing them.

As of 2026, after 7+ years of R&D, NOVOS has achieved all six layers of evidence, with additional research in progress.

Why lifespan experiments are a high bar

Lifespan is surprisingly difficult to move

Scientists have been trying to identify interventions that extend mammalian lifespan for decades. One of the clearest examples is the National Institute on Aging’s Interventions Testing Program, or ITP.

The ITP was created specifically to test candidate interventions for effects on lifespan and healthspan in mice. It does not simply run one experiment in one laboratory. Compounds are tested using standardized protocols across three sites: the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center at San Antonio.

Candidates are selected because researchers already have a scientific reason to think they might work. And yet the current ITP record is remarkably selective. Since the program began in 2002, the NIA reports 15 agents and 2 combinations that have significantly increased median lifespan.²

15Agents

+

2Combinations

Identified by the NIA Interventions Testing Program as significantly increasing median mouse lifespan since 2002.

That distinction is important. We cannot place one NOVOS experiment beside an ITP experiment and call it a head-to-head comparison. They are different studies.

What the ITP does show is something more general: even interventions chosen specifically because scientists think they may extend lifespan often do not. Mechanistic promise is not the same thing as a survival result.

The successful list includes interventions such as rapamycin, acarbose, glycine, astaxanthin and several pharmaceuticals or experimental compounds. There are many more negative results in the program’s public record.

Why test mice?

Why mice remain important in longevity research

Humans are the species we care about. So why spend years studying mice?

Because the ultimate human longevity experiment is extraordinarily difficult. To prove that a nutritional intervention extends human lifespan, researchers would need very large groups of people, extraordinarily long follow-up, strong adherence, careful control of confounding variables, and decades of patience.

That does not mean human longevity science is impossible. It means researchers build evidence in stages.

Cells can reveal mechanisms. Animals allow researchers to study those mechanisms inside a complete organism. And mice have one particularly useful property: their lifespan is short enough that researchers can measure it directly.

A mouse lifespan study can therefore ask a question that a six-month human study cannot: did the treated animals actually survive longer?

Cell

days to weeks
+ tens of thousands of dollars

Mouse

months to years
+ hundreds of thousands of dollars

Human

years to decades
+ millions to tens of millions of dollars

Translation becomes more relevant as evidence moves toward humans, but direct lifespan experiments become dramatically harder.

The tradeoff is obvious. Mice are not small humans. Their metabolism differs. Their diseases differ. Their environment differs. And an intervention that extends mouse lifespan may do nothing of the sort in people.

Mouse lifespan is therefore meaningful preclinical evidence. It is not human proof.

A corridor of ventilated rodent housing racks in an aging-research laboratory — A rodent housing facility. Controlled environments make survival measurable, but they are nothing like the human world.

The NOVOS Core mouse study

So researchers put the complete formula into an aged-mouse lifespan experiment

The new study was conducted by researchers including scientists at Newcastle University and is currently available as a preprint while undergoing peer review.¹

The intervention was not one isolated Core ingredient. It was the full, exact, patent-pending, twelve-component formulation that is sold to consumers:

Pterostilbene01
Glucosamine Sulfate02
Fisetin03
Glycine04
Lithium Aspartate05
Calcium Alpha-Ketoglutarate06
Magnesium Malate07
Vitamin C08
L-Theanine09
Hyaluronic Acid10
Rhodiola Rosea11
Ginger Root Extract12

The researchers compared three groups of naturally aged male C57BL/6J mice:

Age 18 months

Baseline measurements: frailty, body weight, cognition.

Age 20 months: interventions begin

ControlNo active longevity intervention.

EXPERIMENT:
MULTI-INGREDIENT NUTRACEUTICALContinuous administration of the twelve-ingredient NOVOS Core formulation in food.

POSITIVE CONTROL:
SENOLYTIC INTERVENTIONTwo injected treatment courses using Navitoclax plus BAM15, an experimental senescence-targeting strategy with components known to extend mouse lifespan.

Repeated measurements

Frailty, body weight and cognition assessed over time.

Survival follow-up

All groups followed to study endpoint.

Male C57BL/6J mice. Animal study. Not predictive of human lifespan.

What was studied?

Whether late-life intervention with the complete twelve-ingredient NOVOS Core formulation, or an experimental senolytic regimen, could affect survival and healthspan in naturally aged mice.

In what model?

Naturally aged male C57BL/6J mice, with interventions beginning at 20 months of age under a soaked-food feeding protocol associated with caloric excess and metabolic stress.

What was measured?

Survival to endpoint, plus repeated frailty index scoring, body weight and short-term memory assessed by spontaneous alternation in a Y-maze.

What did it find?

Median survival of 703 days in controls versus 830 days with the nutraceutical (about 18% greater; log-rank p = 0.045) and 834 days with the senolytic. A censored sensitivity analysis produced a similar direction of effect.

What does it not prove?

It does not establish human lifespan extension, human healthspan effects, or equivalence between the supplement and senolytic drugs.

Conflicts / funding

Funded through a UK Medical Research Council grant to Thomas von Zglinicki and a donation from NOVOS Labs to Satomi Miwa. Diogo Barardo is an employee of NOVOS Labs. Funders had no role in study design, data collection, analysis, interpretation, manuscript writing, or the decision to publish.

This was also a late-life intervention. Treatment began at 20 months of age. The researchers were therefore not asking whether lifelong supplementation beginning in youth could change mouse lifespan. They were asking whether intervention beginning after substantial biological aging had already occurred – approximately 60 years old in human terms – could still matter.

The result

Median survival increased by about 18%

The primary survival result was straightforward. Median survival in the control mice was 703 days. Median survival in mice receiving the multi-ingredient nutraceutical was 830 days: a difference of 127 days, or approximately 18%. The survival curves were significantly different by log-rank analysis, p = 0.045.¹

Animal study

C (control)NUT (nutraceutical, NOVOS Core)SEN (senolytic)Log-rank p = 0.045

Redrawn natively to match the published survival figure. Hover, tap, or focus the median markers for values. Reported medians and p-value match the primary analysis of the preprint.

703

Control, days

830

Core formulation, days

+127

Days difference

~18%

Animal study

Mouse results do not establish human lifespan extension.

There is an obvious temptation to stop the article here. A longevity formula. A lifespan experiment. Eighteen percent longer median survival. Done.

But that would leave out the most scientifically important part of the paper.

A model of real-world metabolic stress

The mice were in a more "real world" model of metabolic stress

At 20 months, the mice were switched to soaked food to ensure consistent delivery of the intervention. In preliminary feeding measurements, the soaked-food format substantially increased food consumption. The mice also gained considerable body weight.

The authors therefore interpret the study as a model involving caloric excess, obesity and metabolic stress, rather than an optimized aging environment. ¹

That is not a flaw. It is a feature that may make the model more relevant to human aging. Most people do not grow old in pathogen-free laboratories on perfectly controlled diets and schedules. They age amid metabolic stressors: dietary caloric excess, moderate alcohol consumption, inadequate exercise, disrupted sleep, and the accumulated metabolic load of modern life.

In this context, the question is not whether NOVOS Core can extend maximum lifespan in a pristine environment. The question is whether a late-life intervention can preserve survival when aging is already occurring under metabolic stress.

Control in this study703 days

Nutraceutical group (NOVOS Core)830 days

Median survival in the study's control group compared with the nutraceutical group receiving NOVOS Core.

In this experiment, the answer was yes. The intervention increased median survival by roughly 18% under these conditions.

That makes this an interesting model for modern aging. Humans do not grow old in pathogen-free laboratories on perfectly controlled diets and schedules. They age in real environments, with real metabolic pressures. An intervention that preserves survival under caloric excess and metabolic stress may therefore be biologically meaningful.

But the translational relevance needs to be studied in humans; it is not evidence that Core will add 18% to a human lifespan.

A second survival analysis

A senolytic-related complication to note for full transparency

The experiment encountered one technical problem. The senolytic protocol involved injections. A small cluster of deaths occurred across the groups shortly after the first treatment course, which were accounted for in the statistical analysis.

Postmortem findings suggested that some deaths resulted from abdominal infection following accidental puncture of enlarged seminal vesicles, which are common in aged male C57BL/6J mice.

Because those deaths were considered unrelated to biological aging, the researchers performed an analysis censoring the likely procedure-related deaths.

In that analysis, median lifespan was 719 days for controls, 860.5 days for the nutraceutical group, and 852 days for the senolytic group. That corresponded to approximately 19.7% greater median survival for the nutraceutical group and 18.5% for the senolytic group – meaning that NOVOS Core outperformed the positive control.¹

However, the primary uncensored analysis remains the more conservative headline: approximately 18% longer median survival for NOVOS Core versus control. The sensitivity analysis is critical because it shows that the direction of the result was not created by those procedure-related deaths.

Primary survival analysis

All deaths included. Median survival: 703 days (control), 830 days (nutraceutical), 834 days (senolytic). Approximately 18% greater median survival for the nutraceutical versus control, p = 0.045.

Censored sensitivity analysis

Likely procedure-related deaths removed. Median survival: 719 days (control), 860.5 days (nutraceutical), 852 days (senolytic). Approximately 19.7% (nutraceutical) and 18.5% (senolytic) greater median survival for the two active groups versus control.

Why censoring was performed

A cluster of deaths followed the first injection course. Postmortem findings implicated abdominal infection after accidental puncture of enlarged seminal vesicles, a common feature of aged male C57BL/6J mice, rather than biological aging.

Why both are disclosed

The uncensored analysis is the more conservative headline. The censored analysis confirms the direction of the result was not an artifact of procedure-related mortality. Reporting both is the transparent approach.

The senolytic comparison

The other treatment makes the experiment even more interesting

The second intervention was not another supplement. It was an experimental senolytic strategy using Navitoclax plus BAM15.

Senolytics aim to remove senescent cells. Senescent cells are damaged or stressed cells that have stopped dividing but remain metabolically active. As they accumulate, they can release inflammatory and signaling molecules that affect surrounding tissue. Cellular senescence is one of the recognized Hallmarks of Aging.³

The survival result in this particular experiment was strikingly similar between the two active groups. Median survival: 830 days with the continuous nutraceutical versus 834 days with the two-course senolytic regimen.¹

The similar survival curves created an interesting mechanistic question: if Core was producing a comparable survival pattern, was it working by killing senescent cells too?

WAS NOVOS CORE BEHAVING AS A SENOLYTIC?

The cell experiments suggested something subtler

The investigators tested the complete formulation and its individual components in senescent human fibroblasts. They looked for senolytic activity. In other words: did the intervention selectively eliminate senescent cells?

That matters because Fisetin, one of the Core ingredients, is frequently discussed as a potential senolytic. Under the conditions used in this experiment, neither the complete formulation nor the tested individual ingredients showed meaningful selective killing of the senescent fibroblasts.

So the researchers looked at something different: senostatic activity.

Senolytic versus senostatic

A senolytic attempts to remove senescent cells. A senostatic, sometimes called a senomorphic intervention, attempts to reduce the harmful behavior associated with those cells without necessarily killing them. Cellular senescence is one of the 12 Hallmarks of Aging that NOVOS Core was designed to address.

Senolytic

Senescent cell ↓
selective elimination

Remove the cell.

Senostatic

Senescent cell ↓
reduced harmful phenotype

Change what the cell is doing.

When the water-dissolved complete formulation was applied to senescent human fibroblasts, researchers observed reductions in nuclear size, reactive oxygen species, or ROS, and IL-6 secretion, without comparable effects in non-senescent cells.¹ Essentially, this finding confirms that NOVOS Core's formulation does indeed address senescent cells.

Those are laboratory outcomes. They do not demonstrate a senostatic effect in the human body. However, this finding confirms that NOVOS Core's formulation does indeed address senescent cells. And they offer a possible mechanistic explanation that fits another part of the animal data: the benefit from the continuous nutraceutical accumulated gradually rather than appearing suddenly after a short treatment course.

Senescent cells are cells that have stopped dividing but remain metabolically active, secreting inflammatory and signaling molecules collectively called the senescence-associated secretory phenotype, or SASP.

A senolytic removes senescent cells outright. A senostatic (or senomorphic) instead aims to dampen the harmful secretions and behaviors of those cells while leaving them alive.

In this study, the complete formulation did not selectively kill senescent human fibroblasts in vitro, but it did reduce several senescence-associated signals: nuclear size, reactive oxygen species and IL-6 secretion. These are laboratory findings and do not establish a senostatic effect in humans.

Fluorescence microscopy of cultured human fibroblast cells used in cellular senescence research — Simulated image of cultured human fibroblasts under fluorescence microscopy. Laboratory findings in cells do not demonstrate effects in the human body.

What happened to frailty and memory?

Living longer is more interesting if function is preserved too

Lifespan is easy to understand. Healthspan is harder. An intervention that simply prolongs severe frailty would be far less interesting than one that helps preserve function while survival improves.

The investigators therefore repeatedly measured frailty and cognition.

The nutraceutical group showed a gradual attenuation in frailty progression over time. By 30 months, the difference in frailty trajectory was approaching statistical significance rather than meeting a conventional significance threshold.¹

That wording matters. This was a promising directional finding. It was not a definitive statistically significant frailty result.

Short-term memory was assessed using spontaneous alternation in a Y-maze. The nutraceutical-treated animals maintained performance over time while controls declined, although baseline differences and dwindling numbers of surviving control animals limited later comparisons.¹

The senolytic group followed a different pattern. Its strongest frailty and cognitive effects appeared shortly after treatment and diminished later. The continuous nutraceutical showed a slower, more gradual trajectory.

Animal study. Frailty progression showed a gradual favorable trajectory and short-term memory was maintained over time, with limited sample sizes at late timepoints.

What the mouse study does not show

The most important sentence in this article may be this one

NOVOS Core has not been shown to extend human lifespan.

The mouse study cannot answer that question. It also cannot establish that Core adds 18% to human life expectancy, prevents human frailty, prevents cognitive decline, acts as a senostatic in people, or reproduces the senolytic comparison in humans.

There are additional limitations.

What this study does not prove

Only male mice were studied.
The model involved a specific inbred mouse strain.
The animals experienced unusual metabolic stress associated with the feeding protocol.
The control lifespan was shorter than historical expectations.
The study experienced procedure-related mortality.
Some late healthspan comparisons had limited surviving sample sizes.
The manuscript has not yet completed peer review.

Status: Preprint · manuscript under peer review

These are not details to hide. They are the difference between communicating science and advertising a result.

Why the result still matters

Scientific limitations and scientific significance can coexist

There is a tendency in supplement marketing to present every positive result as definitive. There is an equal tendency among skeptics to treat any limitation as a reason to discard the entire experiment. Neither is how science works.

This study asks a legitimate question. A defined twelve-ingredient formulation was administered continuously to naturally aged mice beginning late in life. Survival was prospectively followed. Median survival was significantly greater than controls. The direction remained similar after censoring likely procedure-related deaths. Healthspan measures showed potentially favorable trajectories. And cellular experiments provided a plausible mechanistic signal that was distinct from simple senolytic activity.

That is meaningful preclinical evidence. It simply belongs in the category of animal evidence, not human lifespan proof.

The bigger question

So when is a “longevity supplement” actually being studied for longevity?

Imagine two products.

Product A

Contains an ingredient that extended lifespan in worms. Another ingredient increased NAD+. Another altered mTOR signaling. Another is associated with lower mortality in observational research. Every ingredient has citations. The finished formula has never been tested.

Product B

Also begins with ingredient-level evidence. But the research program continues. The actual formulation is tested in cells. Then in animals. Then in humans. Each stage asks a harder question.

The point is not that Product A contains useless ingredients. It may be thoughtfully formulated. The point is that evidence about ingredients is not evidence about the finished formula.

That distinction becomes increasingly important as formulas grow more complex. Ingredients can interact. One compound can improve the effect of another. It can also do nothing. Or interfere.

The scientific response to that uncertainty is not “trust the ingredient list.” It is: test the combination.

The formula matters

A formula is not simply the sum of its citations

NOVOS Core contains twelve active ingredients. Each was selected in part because of evidence connecting it to biological processes implicated in aging. But that was the beginning of the research strategy, not the desired endpoint.

The formulation was designed around the interconnected Hallmarks of Aging described in modern geroscience.³ Those include processes such as:

Genomic instabilityEpigenetic alterationsLoss of proteostasisDeregulated nutrient sensingMitochondrial dysfunctionCellular senescenceStem-cell exhaustionAltered intercellular communicationInflammagingImpaired autophagyTelomere attritionMicrobiome dysbiosis

These processes interact. Aging does not occur because one molecule becomes too low. That is the rationale for a systems approach. But a systems rationale is still only a hypothesis until the system is tested.

From cells to animals

The mouse study did not appear out of nowhere

Before the lifespan experiment, NOVOS formulations had already been evaluated in laboratory models of aging biology.

In a peer-reviewed study using two-dimensional and three-dimensional human keratinocyte models, researchers examined NOVOS formulations under chemical stress. The experiments measured markers associated with oxidative stress and DNA damage. NOVOS treatment reduced several laboratory signals associated with DNA strand damage in stressed human skin cells.⁴

These are in vitro findings. They do not tell us that someone who drinks Core experiences the same effect in their skin. But they answer a mechanistic question: can the formulation alter aging-relevant cellular responses under controlled conditions?

Other laboratory work has examined oxidative DNA-damage markers and cellular senescence-related phenotypes. And the new mouse paper adds another cellular result: the complete twelve-ingredient formulation reduced selected senescence-associated cellular signals in vitro while showing no direct senolytic activity.¹

Human cellsDNA integrity and stress-response research. In vitro; does not establish effects in the body.

Senescent human fibroblastsSenostatic signals in laboratory conditions. Not a demonstrated human effect.

Aged miceSurvival and healthspan in a living organism. Animal study; not human proof.

Those experiments do not prove longevity in people. That is precisely why the research program needed to move beyond cells.

Then came the mice

The animal experiment asked a harder question

Cells cannot become frail. A petri dish cannot develop cognition. And cultured fibroblasts do not have a lifespan in the organismal sense.

A living mouse integrates metabolism, circulation, immune function, brain function, muscle, organs, hormones, the microbiome, and countless biological interactions that cell culture removes.

That is why a statistically significant survival result in an aged whole-animal model adds a qualitatively different layer of information. The formulation did something in the context of a living aging organism.

Again: that organism was a mouse. But the evidence ladder had moved up one rung.

And then humans

The human study asked a different question

You cannot run an 80-year placebo-controlled lifespan trial every time you want to evaluate a longevity intervention. So human geroscience often relies on functional systems and aging-related biomarkers that can be measured over practical time periods.

For NOVOS Core, the first major physiological system tested in randomized human research was cardiovascular function. That choice was deliberate. Cardiovascular physiology changes substantially with age. Every organ depends on circulation. And vascular function can be measured objectively.

A clinician performing a vascular ultrasound assessment on a participant's arm during a flow-mediated dilation measurement — Flow-mediated dilation assessment: ultrasound measures how well an artery widens in response to increased blood flow.

The STAMINA trial

Researchers at the University of Surrey conducted STAMINA, a randomized, double-blind, placebo-controlled study of the complete NOVOS Core formulation.^5,6 The registered trial enrolled 61 adults aged 40+. Participants were randomized to NOVOS Core or placebo. The intervention lasted 6 months.

The prespecified primary outcome was flow-mediated dilation, or FMD. FMD measures how well an artery widens in response to increased blood flow. The study also measured pulse-wave velocity, a measure related to arterial flexibility, along with blood pressure and other cardiovascular outcomes.

61 randomizedCore vs placeboDouble blind6 monthsFMD · PWV · SBP

At six months, compared with placebo, the study reported:

+2.9 pts

Flow-mediated dilation

Percentage-point difference versus placebo at six months.

1.18 m/s

Pulse-wave velocity

Favorable difference versus placebo in arterial flexibility.

6.1 mmHg

Systolic blood pressure

Favorable placebo-adjusted difference among participants whose pressure was already within the normal range.

Randomized human trial. Adults 40+. Six months. Cardiovascular physiological outcomes. Did not measure lifespan. Manuscript under peer review.⁵

The complete Core formula was the intervention. Not one isolated ingredient. Not a hypothetical ingredient stack. The formula people actually use.

What was studied?

Whether the complete, commercially available NOVOS Core formulation affects vascular function in healthy middle-aged adults.

In what model?

A randomized, double-blind, placebo-controlled human trial sponsored by the University of Surrey, prospectively registered as NCT06145087, enrolling 61 adults aged 40+ for six months.

What was measured?

Flow-mediated dilation as the prespecified primary endpoint, with pulse-wave velocity and blood pressure among secondary outcomes.

What did it find?

At six months versus placebo: +2.9 percentage points in FMD, a 1.18 m/s favorable difference in pulse-wave velocity, and a 6.1 mmHg favorable placebo-adjusted difference in systolic blood pressure among participants already within the normal range.

What does it not prove?

It did not measure lifespan, mortality or disease outcomes, and it does not show that Core extends human life. The manuscript is under peer review.

What STAMINA does and does not add

The human trial does not prove lifespan extension either

This is where it becomes especially important not to blur evidence tiers. The mouse study measured survival. STAMINA did not. STAMINA measured functional cardiovascular physiology.

The trial therefore does not show that Core extends human lifespan. It does not show that Core prevents heart disease. It does not show that Core prevents death. It does not validate an 18% mouse result in humans.

What it does provide is randomized human evidence that the complete formulation can measurably influence multiple physiological systems studied in relation to vascular aging. That is a very different question. And a much more relevant one for human translation than a cell assay alone.

Mouse study

Question: Did survival differ?
Outcome: Median survival
Limit: Does not translate directly to humans

STAMINA

Question: Did human vascular function differ?
Outcomes: FMD, PWV, healthy SBP
Limit: Did not measure human lifespan

NOVOS Core therefore now sits in an unusual scientific position. Its evidence is not based on one perfect experiment. There is no such experiment. Instead, different research models ask different questions: what happens to cells? What happens in an aging organism? What happens to human physiological function?

That is how translational research is supposed to progress.

The current evidence ladder

That Core extends human lifespan.

This is the point

“Longevity” should describe the research program, not replace it

It would be easy to turn all of this into a claim that NOVOS has solved aging. It has not. Nobody has.

It would also be easy to claim that every other product using the word longevity is scientifically empty. That would be unfair. Some products contain very well-studied ingredients. Some companies are doing serious research. Some interventions may eventually prove highly valuable.

The distinction we think matters is simpler: how close has the evidence come to the product you are actually taking?

If the only evidence for a twelve-ingredient product consists of twelve papers studying those ingredients separately, that is one level of evidence. If the finished formulation itself has been evaluated in cells, animals and randomized human research, that is another.

Consumers deserve to know which one they are looking at.

That is the standard NOVOS is trying to push forward. Not “believe us because we call this longevity.” But: here is what has been measured. Here is where it was measured. Here is what it means. Here is what it does not mean.

Why study the complete formula?

Because combination effects cannot be assumed

The supplement industry often treats ingredient evidence as modular. If ingredient A did something useful in Study A, and ingredient B did something useful in Study B, then a product containing both is assumed to deliver both outcomes.

Biology is rarely that tidy. Compounds can share pathways. Compete. Change absorption. Alter metabolism. Amplify an effect. Or blunt one.

The existence of positive studies on the ingredients therefore makes formulation testing more necessary, not less.

The right question is not “do the ingredients have research?” They should. The harder question is: what happens when we combine them exactly this way?

The mouse study asked that question in an aging organism. STAMINA asked it in people. That is the conceptual bridge between the two studies.

Who conducted the mouse study?

Transparency includes who paid for the research

The mouse manuscript lists researchers Charlotte Brookes, Edward Fielder, Evon Low, Diogo Barardo, Thomas von Zglinicki and Satomi Miwa.¹

The study was funded through a UK Medical Research Council grant to Thomas von Zglinicki and a donation from NOVOS Labs to Satomi Miwa. Diogo Barardo is an employee of NOVOS Labs.

The manuscript states that the funders had no role in study design, data collection, analysis, interpretation, manuscript writing, or the decision to publish. The paper also discloses that Satomi Miwa and Thomas von Zglinicki are named inventors on a patent involving the senolytic drug combination used in the comparator arm.

These disclosures do not invalidate the research. They are information readers should have when evaluating it.

Funding

A UK Medical Research Council grant to Thomas von Zglinicki, and a donation from NOVOS Labs to Satomi Miwa.

Affiliations

Diogo Barardo is an employee of NOVOS Labs. Other authors are affiliated with their academic institutions, including Newcastle University.

Funder role

Per the manuscript, the funders had no role in study design, data collection, analysis, interpretation, manuscript writing, or the decision to publish.

Patent disclosure

Satomi Miwa and Thomas von Zglinicki are named inventors on a patent involving the senolytic drug combination used in the comparator arm.

What would make the mouse evidence stronger?

Science is not a finish line

One positive mouse experiment should lead to more experiments. The next useful questions include:

Would the survival effect replicate in another laboratory? Would it reproduce in genetically heterogeneous mice? Would females respond similarly? What happens under a conventional feeding protocol without the metabolic-stress confounder? Which biological mechanisms are most important? Would different start ages change the outcome? Which components of the formula contribute most? Would healthspan effects remain significant with larger late-life sample sizes?

And ultimately: do any of the biological patterns observed in mice correspond to effects measurable in humans?

Those are not weaknesses in the idea of researching Core. They are the research agenda.

A real longevity research program should generate new questions faster than marketing answers them.

Why the human trial matters so much

The mouse result becomes more interesting because the research did not stop with mice

If NOVOS had only an 18% mouse survival result, this article would still be interesting. But it would remain entirely preclinical.

The reason the broader Core story is more meaningful is that the formulation has also moved into randomized human research. STAMINA did not recreate the mouse experiment. That would be impossible over six months. Instead, it asked whether a major aging-related physiological system could be measurably affected in humans.

The study focused on cardiovascular function because vascular aging changes measurably across adulthood, supports every organ through circulation, and can be assessed using validated functional endpoints.

The complete Core formula produced statistically significant placebo-adjusted effects across three independent vascular measures.⁵ That is important precisely because it is a different type of evidence.

Cells tell us about mechanism. Mice tell us what happened to survival in an animal model. Humans tell us whether the formulation can affect measurable physiology in people. No one study substitutes for the others.

The category question, revisited

So what should “longevity supplement” mean?

There is no single perfect test. A product should not need a 60-year mortality trial before anyone is allowed to discuss healthy aging. But the word should carry some scientific responsibility.

At minimum, we think consumers should be able to ask:

Is there a coherent biological rationale?
Are the ingredients actually disclosed?
Is the formula built around aging biology rather than one fashionable molecule?
Has the finished formulation been tested?
Has it moved beyond cells?
Is there animal evidence?
Is there human evidence?
Are the human outcomes relevant to aging physiology?
Are negative findings and limitations disclosed?
Can I see the research?

Those questions create a much more useful standard than “how many longevity buzzwords fit on the label?”

The formula behind the research

NOVOS Core was built to be tested, not simply explained

NOVOS Core contains twelve ingredients selected to address the interconnected biology of aging. But the ingredient list is only the starting point. The more important distinction is what happened next.

The formulation moved through mechanistic research, human-cell experiments, an aged-mouse lifespan study, human observational and pilot work, and randomized, double-blind, placebo-controlled human research.

That does not prove that Core extends human life. It does something more defensible. It provides a growing body of evidence that the finished formulation can measurably interact with biological systems studied in aging research. And it allows consumers to evaluate the product based on more than a collection of ingredient citations.

Official NOVOS Core packaging: the box and a single-serve sachet

The same twelve-ingredient formulation used in the research program, evaluated from cells to a randomized human trial.

CellsAged miceHuman RCT

A different way to think about longevity products

Do not ask only what is inside. Ask what has been tested.

There will probably never be one molecule that defines longevity. Aging is too complex. And there will probably never be one study that proves everything a serious longevity intervention needs to prove.

The better model is cumulative. Biological rationale. Mechanism. Whole-formula testing. Animal evidence. Human physiology. Replication. More human research.

Each step can invalidate what came before. That is a feature of science, not a problem.

For NOVOS, the goal is not to build the best argument around the ingredients. It is to keep testing the formula.

Final limitation

An 18% mouse result is not an 18% human result

NOVOS Core has not been demonstrated to extend human lifespan.
The aged-mouse study does not establish human longevity.
The study was conducted in male C57BL/6J mice under a metabolically stressed feeding model.
The control animals had shorter survival than historical norms.
The authors interpret the result as rescue toward expected lifespan rather than extension of maximum species lifespan.
The study has not yet completed peer review.
STAMINA measured vascular physiology, not lifespan or mortality.
The smaller biological-aging and skin studies have important design and sample-size limitations.

Every one of those statements should remain attached to the evidence. Because the goal is not to make mouse science sound human. The goal is to build the human evidence that eventually matters more.

Longevity science should become harder as it gets better

It is easy to study a molecule in a dish

Harder to test a formulation. Harder still to follow an aging animal for the rest of its life. Harder again to randomize people to a finished formulation and measure real physiological function.

That progression matters.

NOVOS Core is not the answer to human longevity. No supplement can credibly claim that today. But it represents a different approach to building one:

Start with aging biology. Design a system. Test the system. Publish the results. State the limitations. Move closer to humans. Then test again.

That is what a longevity research program should look like.

Built for longevity.
Studied like it.

The complete formula. Tested from cells to humans.

NOVOS Core is a twelve-ingredient longevity formulation designed around the interconnected biology of aging. Its growing research program includes human cellular research, aged-mouse lifespan research, human biological-aging and skin research, and randomized, double-blind, placebo-controlled human clinical research.

Explore NOVOS Core See the Scientific Evidence

Read the Mouse Study

Animal studies do not establish human lifespan extension. Human randomized research evaluated cardiovascular function, not lifespan. Individual results vary.

References

The research behind this article

[1]

Rescuing Healthspan in Obese, Aged Mice: A Comparison between Multi-Ingredient Nutraceuticals and Senolytic Interventions

Brookes C, Fielder E, Low E, Barardo D, von Zglinicki T, Miwa S. Preprints.org. Posted December 31, 2025. Animal study (aged male C57BL/6J mice).

PreprintUnder peer reviewAnimal study

SupportsIntervention beginning at 20 months; complete twelve-ingredient formulation; median control survival 703 days; nutraceutical median survival 830 days; approximately 18% greater median survival versus control; p = 0.045; censored sensitivity analysis; metabolic-stress interpretation; senolytic comparator; frailty and cognitive findings; absence of direct senolytic activity; senostatic cellular signals; study limitations; funding and conflict disclosures.ImportantAnimal research. Does not establish human lifespan extension.

View paper

[2]

Interventions Testing Program

National Institute on Aging. Current program information, 2026.

Research program

SupportsITP established to test interventions for mouse lifespan and healthspan; testing performed across three research sites; 15 agents and 2 combinations currently listed as significantly increasing median lifespan since the program began in 2002.ImportantThe ITP does not constitute a direct comparison with the NOVOS experiment. Study models and protocols differ.

View program

[3]

Hallmarks of Aging: An Expanding Universe

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Cell. 2023;186:243-278. DOI: 10.1016/j.cell.2022.11.001. Review.

Peer reviewedReview article

SupportsModern Hallmarks of Aging framework; interconnected biological mechanisms of aging.

View paper

[4]

Promising Effects of Novel Supplement Formulas in Preventing Skin Aging in 3D Human Keratinocytes

Nutrients. 2024;16(16):2770. In vitro study.

Peer reviewedIn vitro

SupportsPeer-reviewed in vitro research involving NOVOS formulations; human keratinocyte stress models; DNA-damage response markers; oxidative-stress biology.ImportantLaboratory research only. Does not establish effects in humans.

View paper

[5]

Acute and 6-Month Vascular Effects of a Multi-Component Nutritional Supplement: A Randomised Controlled Trial

Piercy C, Harris J, Sackho K, Campagnolo P, Barardo D, Creagh-Brown B, Heiss C. SSRN preprint. 2026. DOI: 10.2139/ssrn.6241278. ClinicalTrials.gov: NCT06145087. Randomized, double-blind, placebo-controlled human trial.

Under peer reviewHuman RCT

SupportsSTAMINA results; randomized human trial; complete NOVOS Core formulation; adults aged 40+; six-month intervention; flow-mediated dilation; pulse-wave velocity; systolic blood pressure.

View paper

[6]

Investigation of Short and Intermediate Term Effects of a Supplement Mix Designed to Target Ageing Mechanisms on Vascular Function in Healthy Middle-aged Participants (STAMINA)

ClinicalTrials.gov. NCT06145087. Trial registration.

Trial registration

SupportsProspective trial registration; University of Surrey sponsorship; randomized design; double-blinding; actual enrollment of 61; FMD as primary endpoint; PWV and blood pressure as secondary outcomes; complete commercially available NOVOS Core as intervention.

View registration

Disclaimer

This article is for educational purposes.

Animal research does not establish that NOVOS Core extends human lifespan or produces the same effects in people. The mouse study described here was conducted in aged male mice under specific experimental conditions. The manuscript is publicly available as a preprint and is currently under peer review.

NOVOS Core has not been demonstrated to extend human lifespan.

The STAMINA human trial evaluated cardiovascular and vascular-function biomarkers, not lifespan, mortality or disease outcomes.

NOVOS Core is a dietary supplement and is not intended to diagnose, treat, cure or prevent disease. These statements have not been evaluated by the Food and Drug Administration.

Individual results vary.